Description:
MGL-3196 is a first-in-class, orally available, once-daily and liver-directed thyroid hormone receptor (THR) beta-selective agonist. Studies suggest that MGL-3196 has an attractive, differentiated profile as a potential treatment for non-alcoholic steatohepatitis (NASH) and dyslipidemias.
- Molecular Weight: 435.211
- Molecular Formula: C17H12Cl2N6O4
Canonical SMILES:
CC(C)C1=CC(=NNC1=O)OC2=C(C=C(C=C2Cl)N3C(=O)NC(=O)C(=N3)C#N)Cl
InChI:
InChI=1S/C17H12Cl2N6O4/c1-7(2)9-5-13(22-23-15(9)26)29-14-10(18)3-8(4-11(14)19)25-17(28)21-16(27)12(6-20)24-25/h3-5,7H,1-2H3,(H,23,26)(H,21,27,28)
InChIKey: FDBYIYFVSAHJLY-UHFFFAOYSA-N- Application: potential treatment for non-alcoholic steatohepatitis (NASH) and dyslipidemias
Synonyms:
CHEMBL3261331; UNII-RE0V0T1ES0; MGL-3196; MGL 3196; MGL3196; VIA 3196; VIA3196; VIA-3196; Resmetirom.RE0V0T1ES0; 2-[3,5-dichloro-4-[(6-oxo-5-propan-2-yl-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile
More details are to be found on supplier website
